Adjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Governs coverage and prior authorization for adjunctive laboratory and device-based tests (TissueCypher, EsoCheck/EsoGuard, BarreGEN) used to screen, surveil, or risk-stratify patients with or at risk for Barrett esophagus for Blue Cross Blue Shield - Rhode Island members.
No material clinical or coverage changes in this revision.
Coverage Criteria — Adjunctive Tests for Barrett Esophagus
Not covered / Not medically necessary
Tests considered not covered / not medically necessary for Medicare Advantage and Commercial Products unless otherwise specified:
[[chunk 3]]
[[chunk 3, chunk 14]]
[[chunk 3, chunk 14]]
Some genetic testing services may be contractually excluded for self-funded groups under the state's Biomarker Testing Mandate (R.I.G.L. §27-1981). Refer to the member's Benefit Booklet or plan documents to determine whether a specific service is excluded or subject to customized coverage for that member.
Coverage and benefits are governed by the member's subscriber agreement, member certificate, and/or the employer agreement. Those documents supersede the provisions of this medical policy; for member-specific coverage and eligibility, contact the provider call center.
The following tests are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products because evidence is insufficient to demonstrate improvement in net health outcome: EsoCheck/EsoGuard, TissueCypher, and BarreGEN.
Services determined to be not medically necessary (or classified as non-covered benefits) are not payable. Providers may not charge the member for such services unless the member has been informed in advance and has agreed in writing to assume financial responsibility.
Coding and Billing
| 0108U | Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer (TissueCypher) |
| 0114U | Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus (EsoCheck/EsoGuard) |
| 81479 | Unlisted molecular pathology procedure (used for BarreGEN) |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Required
Prior authorization is required for Medicare Advantage plans and is recommended for Commercial products. All unlisted genetic or molecular testing CPT codes (for example, 81479) require prior authorization to determine what service is being rendered and whether the service is covered or medically necessary.
- Prior authorization obtained via the online tool for participating providers.
- Unlisted CPT codes: 81479 (Unlisted molecular pathology procedure)
Prior Authorization and Benefits Verification
Verify member-specific benefits and eligibility prior to providing services. Benefits and eligibility are determined by the member's subscriber agreement, member certificate, and/or employer agreement; contact the provider call center for verification. Services determined not to be medically necessary or not covered may be denied and the provider may not charge the member unless the member has provided written agreement in advance.
- Contact provider call center for member-specific benefits and eligibility.
- Do not bill the member for services denied as not medically necessary unless documented written agreement exists.
Prohibition on Laboratory or Third-Party Authorization Assistance
If a laboratory or any third party assists in obtaining authorization, facilitates the authorization process, prepares documentation for clinical appropriateness, or participates in any appeal on behalf of the ordering physician, BCBSRI will deem this a violation of policy. Such actions may result in severe sanctions up to and including termination from the BCBSRI provider network. If a laboratory provides a laboratory service that has not been authorized, the service will be denied and the financial liability will fall on the participating laboratory; the service may not be billed to the member.
- Laboratories and their representatives are prohibited from obtaining authorization or participating in the authorization or appeal process on behalf of the ordering physician.
- Unauthorized laboratory services will be denied and the laboratory is financially responsible; cannot bill the member.
Documentation for Unlisted CPT Codes
For services filed with an Unlisted CPT code (for example, 81479 for BarreGEN) prior authorization is required and providers must supply documentation establishing what service was performed and the medical necessity for that service. When an unlisted code is used, the medical necessity criteria in the Proprietary Laboratory Analyses (PLA) and Multianalyte Assays with Algorithmic Analyses (MAAA) policies will be applied as applicable.
- All Unlisted genetic/molecular testing CPT codes require prior authorization to determine coverage and medical necessity.
- Documentation must clearly describe the service rendered when an Unlisted CPT is billed.
Denial Risk and Member Billing
Services determined to be not medically necessary or not covered under the member's benefit may be denied. Providers must follow authorization requirements and may not charge members for denied services except as allowed by the member's written advance agreement. Refer to participation agreements for additional billing obligations and restrictions.
- Denials may result if authorization is not obtained or medical necessity is not met.
- Providers may not charge members for non‑covered or not medically necessary services unless the member agreed in writing in advance.
Background
Barrett esophagus (BE) is the replacement of the normal squamous epithelium of the distal esophagus with specialized columnar intestinal-type epithelium confirmed by biopsy demonstrating intestinal metaplasia. BE confers an increased risk of progression to esophageal adenocarcinoma; surveillance and management are stratified by the presence and grade of dysplasia to guide surveillance intervals and consideration of endoscopic eradication therapy. Adjunctive tests aim to augment detection or risk stratification but require evidence of improved health outcomes to be considered medically necessary.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.